An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms

Abstract

Various recently reported mutant variants, candidate and urgently approved current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many current situations with severe neurological damage and symptoms as well as respiratory tract disorders have begun to be reported. In particular, drug, vaccine, and neutralizing monoclonal antibodies (mAbs) have been developed and are currently being evaluated in clinical trials. Here, we review lessons learned from the use of novel mutant variants of the COVID-19 virus, immunization, new drug solutions, and antibody therapies for infections. Next, we focus on the B 1.1.7, B 1.351, P.1, and B.1.617 lineages or variants of concern that have been reported worldwide, the new manifestations of neurological manifestations, the current therapeutic drug targets for its treatment, vaccine candidates and their efficacy, implantation of convalescent plasma, and neutralization of mAbs. We review specific clinical questions, including many emerging neurological effects and respiratory tract injuries, as well as new potential biomarkers, new studies in addition to known therapeutics, and chronic diseases of vaccines that have received immediate approval. To answer these questions, further understanding of the burden kinetics of COVID-19 and its correlation with neurological clinical outcomes, endogenous antibody responses to vaccines, pharmacokinetics of neutralizing mAbs, and action against emerging viral mutant variants is needed.

Examining the Associations between COVID-19-Related Psychological Distress, Social Media Addiction, COVID-19-Related Burnout, and Depression among School Principals and Teachers through Structural Equation Modeling

“…However, early hopes of a fully effective vaccine were soon blighted, following the discovery of new variants of the virus, neurological diseases, and other symptoms and long-term effects reported in COVID-19 patients. In light of these emerging developments, the potential for the pandemic to reach uncontrollable levels was also talked 2 of 19 of [4]. Much has been revealed about SARS-CoV-2 through scientific research, which has subsequently led to unprecedented scientific progress in the development of COVID-19 vaccines.…”

Dentists' Stress During the COVID-19 Pandemic: A Repeated Cross-Sectional Study

“…11 Whilst vaccination and treatment were being delivered, several COVID-19 mutant strains with increased virulence and decreased vaccine sensitivity arose. 12 , 13 , 14 , 15 In 2022, the infection rate was much greater. 11 More fetal and infectious strains continued to proliferate.…”

Systematic Review of the SARS-CoV-2 Viral Vector Vaccine AstraZeneca (Azd1222)

“…This is because RNA polymerases do not have any proofreading ability. Many variants of SARS-CoV-2 have been reported, some of them are variants of interest (VOI) and others are variants of concern (VOC) [3,7]. The emergence of new variants is the reason due to which the effectiveness of various vaccines is decreasing [8].…”